Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors - 20/02/21
, R. Calin a, b, P. Flandre b, R. Tubiana a, b, M.-A. Valantin a, b, E. Caumes a, b, C. Katlama a, b, V. Pourcher a, bBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | ART-containing integrase inhibitors could be associated with higher incidence of TB-associated IRIS. |
• | Prospective studies are needed to better characterize the risk of IRIS-TB and to determine the optimal ART regimen for TB-HIV coinfected patients. |
Abstract |
Background |
Tuberculosis is associated with a risk of immune reconstitution inflammatory syndrome (IRIS) after ART initiation.
Methods |
Data from all patients with newly diagnosed tuberculosis disease and uncontrolled HIV infection from 1997 to 2017 in a French center were retrospectively collected. We evaluated the incidence of tuberculosis-IRIS in patients initiating ART with or without integrase inhibitors (INSTI)
Results |
Fifty-five patients were included: 21 receiving an INSTI regimen and 34 a non-INSTI regimen. Except with regard to ART regimen, the two groups were comparable (median CD4 of 85/mm3). The overall percentage of IRIS was 34% (19/55), with 52% IRIS in INSTI regimen and 23% in non-INSTI regimen respectively (P=0.04). In a multivariate logistic model, we observed an increased risk of IRIS in the INSTI regimen compared to the non-INSTI, with an OR at 3.33 [95% CI, 1.01–11.1] (P=0.05)
Conclusions |
ART containing integrase inhibitors could be associated with increased incidence of TB-associated IRIS.
Le texte complet de cet article est disponible en PDF.Keywords : HIV, IRIS-associated tuberculosis, Integrase inhibitors, INSTI
Plan
Vol 51 - N° 1
P. 90-93 - février 2021 Retour au numéro
Article précédent
- Genesis and dissemination of a controversial disease: Chronic Lyme
- X. Gocko, P. Tattevin, C. Lemogne
- Low immune response rate of HIV-infected patients to a single injection of hepatitis A vaccine
- L. Noël, R. Tubiana, A. Simon, M.-A. Valantin, R. Palich, C. Blanc, C. Katlama, A.-G. Marcelin, V. Calvez, E. Todesco
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?